Calcitonin Gene-Related Peptide (CGRP) Antagonists and Their Use in Migraines

被引：7

作者：

Henson, Brianna ^{[1
]}

Hollingsworth, Hanna ^{[2
]}

Nevois, Erika ^{[3
]}

Herndon, Chris ^{[4
]}

机构：

[1] Wake Forest Baptist Hlth Brenner Childrens Hosp, Winston Salem, NC USA

[2] Parkland Hlth & Hosp Syst, Dallas, TX USA

[3] CVS Pharm, Springfield, IL USA

[4] Southern Illinois Univ Edwardsville, Sch Pharm, 200 Univ Pk Dr, Edwardsville, IL 62026 USA

来源：

JOURNAL OF PAIN & PALLIATIVE CARE PHARMACOTHERAPY | 2020年 / 34卷 / 01期

关键词：

CGRP; migraine; calcitonin gene-related peptide; erenumab; galcanezumab; fremanezumab; DOUBLE-BLIND; EPISODIC MIGRAINE; RECEPTOR ANTAGONISTS; PREVENTIVE TREATMENT; EFFICACY; SAFETY; ANTIBODY; PHASE-2; TRIAL;

D O I：

10.1080/15360288.2019.1690616

中图分类号：

R614 [麻醉学];

学科分类号：

100217 ;

摘要：

Migraine is highly prevalent and associated with a large socio-economic burden in the United States. Current preventive medications have variable efficacy and their use is often limited by intolerable side effects. Calcitonin gene-related peptide (CGRP) has been identified as an integral part of migraine pathophysiology. There are currently seven CGRP antagonists under investigation, all of which are undergoing or have completed phase 3 clinical trials. Three of the investigated CGRP antagonists are approved for use within and outside of the United States. The trials have resulted in positive efficacy and safety data. The purpose of this review is to evaluate the seven CGRP antagonists and their future place in therapy.

引用

页码：22 / 31

页数：10

共 50 条

[31] The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy
Raffaelli, Bianca
Reuter, Uwe
NEUROTHERAPEUTICS, 2018, 15 (02) : 324 - 335
[32] New Trends in Migraine Pharmacology: Targeting Calcitonin Gene-Related Peptide (CGRP) With Monoclonal Antibodies
Scuteri, Damiana
Adornetto, Annagrazia
Rombola, Laura
Naturale, Maria Diana
Morrone, Luigi Antonio
Bagetta, Giacinto
Tonin, Paolo
Corasaniti, Maria ziana
FRONTIERS IN PHARMACOLOGY, 2019, 10
[33] Galcanezumab Anti-calcitonin gene-related peptide (CGRP) MAb Treatment for migraine Treatment for cluster headache
Haddley, K.
DRUGS OF THE FUTURE, 2017, 42 (08) : 469 - 477
[34] Benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists: Optimization of the 4-substituted piperidine
Burgey, Christopher S.
Stump, Craig A.
Nguyen, Diem N.
Deng, James Z.
Quigley, Amy G.
Norton, Beth R.
Bell, Ian M.
Mosser, Scott D.
Salvatore, Christopher A.
Rutledge, Ruth Z.
Kane, Stefanie A.
Koblan, Kenneth S.
Vacca, Joseph P.
Graham, Samuel L.
Williams, Theresa M.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (19) : 5052 - 5056
[35] Raynaud's Phenomenon Associated With Calcitonin Gene-Related Peptide Monoclonal Antibody Antagonists
Evans, Randolph W.
HEADACHE, 2019, 59 (08): : 1360 - 1364
[36] Developments in targeting calcitonin gene-related peptide
Alabbad, Sawsan
Figueredo, Nathalia
Yuan, Hsiangkuo
Silberstein, Stephen
EXPERT REVIEW OF NEUROTHERAPEUTICS, 2024, 24 (05) : 477 - 485
[37] Novel peptide calcitonin gene-related peptide antagonists for migraine therapy
Killoran, Patrick M.
Capel, Vicky
D'Aloisio, Vera
Schofield, Adam
Aczel, Timea
Bolcskei, Kata
Helyes, Zsuzsanna
von Mentzer, Bengt
Kendall, David A.
Coxon, Chris R.
Hutcheon, Gillian A.
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2023, 75 (12) : 1581 - 1589
[38] Calcitonin gene-related peptide-targeted therapies are effective options for the prevention and treatment of migraine
Nie, Tina
DRUGS & THERAPY PERSPECTIVES, 2023, 39 (06) : 195 - 199
[39] The evolving landscape and research trend of calcitonin gene-related peptide in migraine: A bibliometric analysis and visualization
Wang, Liwei
Wang, Qing
Diao, Huaqiong
Liu, Xueying
Zhao, Yonglie
FRONTIERS IN NEUROLOGY, 2024, 15
[40] Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis
Hong, Peiwei
Wu, Xintong
Liu, Yao
CLINICAL NEUROLOGY AND NEUROSURGERY, 2017, 154 : 74 - 78

← 1 2 3 4 5 →